Solid Biosciences (NASDAQ:SLDB) and AIM ImmunoTech (NYSE:AIM) Head-To-Head Contrast

Solid Biosciences (NASDAQ:SLDBGet Rating) and AIM ImmunoTech (NYSE:AIMGet Rating) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends and valuation.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Solid Biosciences and AIM ImmunoTech, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Solid Biosciences 0 1 2 0 2.67
AIM ImmunoTech 0 0 0 0 N/A

Solid Biosciences presently has a consensus target price of $4.50, suggesting a potential upside of 493.12%. Given Solid Biosciences’ higher possible upside, research analysts clearly believe Solid Biosciences is more favorable than AIM ImmunoTech.

Risk & Volatility

Solid Biosciences has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500. Comparatively, AIM ImmunoTech has a beta of -0.47, meaning that its stock price is 147% less volatile than the S&P 500.

Profitability

This table compares Solid Biosciences and AIM ImmunoTech’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Solid Biosciences -660.25% -37.71% -33.77%
AIM ImmunoTech -13,933.81% -32.98% -32.06%

Institutional and Insider Ownership

67.0% of Solid Biosciences shares are owned by institutional investors. Comparatively, 16.1% of AIM ImmunoTech shares are owned by institutional investors. 14.8% of Solid Biosciences shares are owned by insiders. Comparatively, 0.0% of AIM ImmunoTech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Solid Biosciences and AIM ImmunoTech’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Solid Biosciences $13.62 million 6.28 -$72.19 million ($0.72) -1.05
AIM ImmunoTech $140,000.00 248.90 -$19.13 million ($0.40) -1.81

AIM ImmunoTech has lower revenue, but higher earnings than Solid Biosciences. AIM ImmunoTech is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Solid Biosciences beats AIM ImmunoTech on 7 of the 12 factors compared between the two stocks.

About Solid Biosciences

(Get Rating)

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

About AIM ImmunoTech

(Get Rating)

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat genital warts, a sexually transmitted disease. It has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.